Al­ny­lam will hire 100 for its new UK of­fice; Puma shares surge as FDA ac­cepts ner­a­tinib NDA

Brex­it Shmex­it. Cam­bridge, MA-based Al­ny­lam is open­ing up a new of­fice in the UK with plans to add 100 staffers to its core team as the biotech starts to steer its RNAi pipeline drugs to Eu­ro­pean ap­provals. The new of­fice is slat­ed for Maid­en­head, “with its strong aca­d­e­m­ic and clin­i­cal re­search sec­tor, as well as its uni­ver­sal health ser­vice and reg­u­la­to­ry bod­ies con­stant­ly striv­ing to be more stream­lined and ef­fi­cient, the UK has a lot to of­fer as a de­vel­op­ment hub for in­no­v­a­tive med­i­cines,” added Bren­dan Mar­tin, Gen­er­al Man­ag­er for UK & Ire­land at Al­ny­lam. “Our in­vest­ment here sig­nals a trust that the UK com­mu­ni­ty will con­tin­ue to treat this mis­sion with the ur­gency and im­por­tance it de­serves.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER